Respiratory Pathogen Panel

Respiratory Testing

Upper respiratory infection is responsible for many life-threatening illnesses. Clarity Labs offers an advanced multiplexed molecular respiratory pathogen panel developed to broaden and streamline testing for multiple viral and bacterial agents of the upper respiratory tract.

The test is a comprehensive, robust assay that detects multiple respiratory pathogens simultaneously in a closed-tube and easy–to-use system.

Why Test for Respiratory Pathogens?

  • More answers
  • Within shorter period of time
  • When it matters most

Due to the inherent faults in screening tests, negative and positive flu screens alike should be verified and differentiated by molecular testing. By ordering this Panel, Providers can distinguish between different Respiratory Pathogens where symptoms may present similarly. Specifically in 2021 with COVID-19, Influenza A & B (Flu), and RSV can be differentiated using this RPP panel.

What to expect with Clarity Labs RPP?

Rapid, Accurate, Reliable Results

  • Remarkable Detection Capabilities
  • Rapid Turnaround Time 24
  • 48 hours After Receipt at Lab
  • Closed-Tube System Minimizes Contamination Risks

4 Testing Panel

Influenza A
Influenza B
COVID-19 SARS CoV-2Respiratory Synctial Virus (RSV)

To learn how to implement our Respiratory Pathogen Panel in your facility, please contact us call (732) 595 5414


RPP Testing:

  • RPP test pinpoints the influenza virus, along with a number of other respiratory viruses and pneumonia causing bacteria, so that physicians can render treatment swiftly and accurately; possibly reducing the severity and duration of infection.

  • Treatment protocols for bacterial pathogens and viral pathogens are vastly different – identifying the pathogen is key to proper and effective treatment.

  • Molecular testing is far superior to screen testing traditionally used in physicians’ offices.

  • Molecular testing is faster than viral culture.

  • RPP test is a multiplex assay differentiating 13 strains of respiratory viruses, and three species of bacteria.

  • Patient populations benefit from this test by precise detection and treatment protocols based on their infection state.

  • Communities – hospitals, schools, corporations, long-term care facilities – can utilize the test’s multiplex capabilities to implement proper quarantine procedures for patients infected with highly transmissible diseases and provide timely treatment to contain and cure infected individuals.

  • The limits on molecular testing are far superior to conventional screen methods – they utilize PCR (Polymerase Chain Reaction) technology, allowing small quantities of nucleic acid to be amplified into detectable levels.

Screen Testing:

  • Is highly dependent on proper specimen collection and preparation.

  • Requires a large input of virus/bacteria to work effectively.

  • Is accurate 89-100% of the time when the patient has a high viral infection, but fails 40-69% of the time when the patient’s viral infection is above or below the established sensitivity of the screen.

  • Is fraught with false positives and false negatives due to inconsistencies in sample collection and preparation.

  • Doesn’t differentiate which species of flu the patient has.

  • Conventional culture and sensitivity testing (which is standard) can take from a few days to a week to get results.


Contact Us
Requisition Forms